课题基金 / 基金详情

Frontiers Clinical and Translational Science Institute at the University of Kansas

Frontiers Clinical and Translational Science Institute at the University of Kansas
堪萨斯大学前沿临床与转化科学研究所
批准号:
10702087
负责人:
Mario Castro
金额:
$11.23万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-09-07 至 2027-06-30

项目摘要

项目成果

Mario Castro的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
OVERALL UL1 PROJECT SUMMARY/ABSTRACT The Frontiers Clinical and Translational Science Institute at the University of Kansas (Frontiers) has been a catalyst for clinical and translational research (CTR) across the Kansas City region. The vision of Frontiers 3.0 is to transform the way we do CTR and ensure that research is rapidly translated to the point of care in a way that improves health for underserved and excluded populations, especially those in rural communities. To do so, we have expanded Frontiers 3.0 partners to include multiple academic institutions, healthcare systems, and community organizations and patient advocacy groups across Kansas and western Missouri. Our new shared leadership structure balances power across institutions. The overall aims of Frontiers are: Aim 1. Train a diverse workforce that leverages multiple disciplines, frameworks and approaches to stimulate creative, responsive and impactful T1-T4 clinical and translational research. Frontiers cores and its KL2 and TL1 programs provide high quality training, assistance in research design and implementation, guidance in applying for grants, and support for career advancement for all levels translational research trainees. In Frontiers 3.0 we emphasize identifying and supporting investigators from underrepresented groups and those with a research focus on underserved and excluded populations. Aim 2. Collaborate and engage with underserved and excluded communities to ensure that clinical and translational research is responsive to their priorities and achieves greater health equity. Frontiers 3.0 hosts Design Studios, Fieldwork Nano-experiences, Story-telling sessions, Community Co- Investigator Human Subjects Training and Conferences to support collaborations between researchers and patients, communities, and stakeholders. New advisory groups of community partners and community- engaged researchers provide guidance at all levels of Frontiers decisionmaking. We expand our novel efforts to understand and address COVID-19 across the lifespan and among underserved and excluded groups. Aim 3. Drive innovative, quality, and efficient clinical and translational research across the lifespan that harnesses novel informatics, genomics, team science and implementation methods to enhance delivery of high-quality healthcare in the region. Frontiers reduces barriers to entering CTR by providing unparalleled comprehensive support that minimizes regulatory burden and expedites research. New cores provide entre to tools and data for pursuing genomic medicine and help investigators access and analyze rich datasets available via clinical informatics. New leadership in Team Science will map investigator networks, identify gaps, and introduce individual and team- level interventions to help investigators build and maintain effective teams. Frontiers will accelerate CTR in the Midwest and build a workforce that attends to health priorities for the rural, underserved, and excluded. Our discoveries and new tools will contribute to knowledge for the nation.
期刊论文(109)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.ncl.2018.01.006
发表时间: 2018-05
期刊: Neurologic clinics
影响因子: 2.4
作者: [Barnett C, Herbelin L, Dimachkie MM, Barohn RJ]
通讯作者: Barohn RJ
DOI: 10.1111/cts.13399
发表时间: 2022-11
期刊: Clinical and translational science
影响因子: --
作者: []
通讯作者:
DOI: 10.1007/s11606-021-06902-6
发表时间: 2022-01
期刊: Journal of general internal medicine
影响因子: 5.7
作者: [Parente DJ, Murray MJ, Woodward J]
通讯作者: Woodward J
DOI: 10.1089/ten.teb.2021.0094
发表时间: 2022-08
期刊: TISSUE ENGINEERING PART B-REVIEWS
影响因子: 6.4
作者: [Knewtson, Kelsey E., Ohl, Nathan R., Robinson, Jennifer L.]
通讯作者: Robinson, Jennifer L.
69
    University of Kansas' Precision Biologic Interventions for Severe Exacerbation Prone Asthma (PrecISE) Clinical Center
    University of Kansas' Precision Biologic Interventions for Severe Exacerbation Prone Asthma (PrecISE) Clinical Center
    WASHINGTON UNIVERSITY'S PRECISION BIOLOGIC INTERVENTIONS FOR SEVERE EXACERBATION PRONE ASTHMA (PRECISE) CLINICAL CENTER
    • 批准号:
      9751957
    • 项目类别:
    • 资助金额:
      $6.53万
    • 财政年份:
      2017
    • 负责人:
      Mario Castro
    • 依托单位:
    Frontiers Clinical and Translational Science Institute at the University of Kansas
    海外基金